No Data
ORBUSNEICH: Annual Report 2024
Are OrbusNeich Medical Group Holdings Limited's (HKG:6929) Fundamentals Good Enough to Warrant Buying Given The Stock's Recent Weakness?
Jianyin International: Raised ORBUSNEICH (06929) Target Price to HKD 6.45, maintaining an "Outperform Market" rating.
The bank indicated that the performance in the second half of 2024 and for the entire year exceeds expectations, with net income of 21 million USD and 40 million USD, respectively, which is 39% and 18% higher than the bank's expectations; total revenue year-on-year increased by 18% and 7%, exceeding the bank's expectations by 7% and 3%.
ORBUSNEICH (6929.HK): Innovation and integration are poised to take off, showing remarkable resilience against the trend.
In the globalization wave of the medical instruments Industry, true game-changers often need to possess both technical penetration and localized wisdom. In the field of cardiovascular interventional instruments, known as the 'Imperium Crown' of the medical industry, ORBUSNEICH has leveraged 25 years of deep cultivation to deliver China's intelligent manufacturing surgical balloons and Brackets to operating rooms in over 70 countries globally, becoming the 'invisible champion' in catheterization laboratories of top hospitals in Europe and America, and establishing a three-dimensional sales network across Asia, Europe, and America. Recently, ORBUSNEICH released its 2024 performance report, unveiling the advancement secrets of this globalization pioneer: the company is navigating the complexities of unpredictable geopolitical situations and significant volatility in the Forex market.
Selected announcements | XIABUXIABU expects a revenue decline of 20% in 2024; Nayuki's Tea expects an adjusted net loss of approximately 0.88 billion yuan to 0.97 billion yuan in 2024.
UNITEDENERGY GP: It is expected to make a profit of 1.4 billion to -1.65 billion HK dollars in 2024, achieving a turnaround from losses compared to the previous year.
ORBUSNEICH (06929.HK) revenue steadily increased to 0.164 billion dollars in the fiscal year 2024, with a year-on-year revenue increase of 43.7% in the Asia-Pacific market.
On March 7, Gelonghui丨ORBUSNEICH (06929.HK) announced its annual performance. For the year ending December 31, 2024, the group's revenue was 0.164 billion USD, a year-on-year increase of 6.6%, driven by the recovery of sales in the USA market and continued growth in the Asia-Pacific region. Excluding the impact of exchange rate fluctuations, the year-on-year revenue growth rate was 8.7%. In 2024, sales reached 1.7 million units, of which 1.5 million units were proprietary products, a year-on-year increase of 4.8%. Gross profit increased by 7.5% to approximately 0.114 billion USD, and the profit attributable to the company’s owners reached 39.717 million USD. The Asia-Pacific region is a集
Some Confidence Is Lacking In OrbusNeich Medical Group Holdings Limited (HKG:6929) As Shares Slide 28%
